Published in Arch Ophthalmol on February 01, 2011
Evaluation of masking study participants to intravitreal injections in a randomized clinical trial. Arch Ophthalmol (2012) 0.75
Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2010) 10.28
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med (2015) 7.08
Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology (2006) 5.79
Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology (2011) 4.15
A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology (2007) 3.49
A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology (2005) 3.20
Age-related macular degeneration is the leading cause of blindness... JAMA (2004) 3.18
Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol (2003) 3.17
Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol (2009) 2.84
Visual acuity as an outcome measure in clinical trials of retinal diseases. Ophthalmology (2007) 2.69
Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology (2012) 2.68
Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology (2007) 2.58
Identification of the tracheal and laryngeal afferent neurones mediating cough in anaesthetized guinea-pigs. J Physiol (2004) 2.50
Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology (2005) 2.43
Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. Arch Ophthalmol (2003) 2.30
Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in age-related macular degeneration. Invest Ophthalmol Vis Sci (2011) 2.23
Visual acuity outcomes among sham vs no-treatment controls from randomized trials. Arch Ophthalmol (2009) 2.15
Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol (2004) 2.12
Radiation retinopathy after fractionated stereotactic radiotherapy for optic nerve sheath meningioma. Ophthalmology (2004) 2.09
Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. Am J Ophthalmol (2003) 2.06
Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials. Arch Ophthalmol (2009) 2.06
Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol (2005) 2.05
Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology (2010) 2.02
RANIBIZUMAB PLUS PROMPT OR DEFERRED LASER FOR DIABETIC MACULAR EDEMA IN EYES WITH VITRECTOMY BEFORE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina (2015) 1.99
Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial--VIP report no. 3. Ophthalmology (2003) 1.96
Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report no. 11. Ophthalmology (2004) 1.96
Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol (2007) 1.89
Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci (2009) 1.88
Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology (2005) 1.80
Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol (2009) 1.72
The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials. Ophthalmology (2007) 1.63
Multisite comparison of high-sensitivity multiplex cytokine assays. Clin Vaccine Immunol (2011) 1.62
Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology (2008) 1.60
Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: quality-of-life findings: SST report no. 12. Ophthalmology (2004) 1.57
Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. Retina (2010) 1.54
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. Arch Ophthalmol (2002) 1.53
Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology (2011) 1.52
Vitamin usage patterns in the prevention of advanced age-related macular degeneration. Ophthalmology (2007) 1.51
Health- and vision-related quality of life among patients with choroidal neovascularization secondary to age-related macular degeneration at enrollment in randomized trials of submacular surgery: SST report no. 4. Am J Ophthalmol (2004) 1.50
Progression of age-related macular degeneration after cataract surgery. Arch Ophthalmol (2009) 1.49
Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions: submacular surgery trials report no. 7. Arch Ophthalmol (2005) 1.47
Diabetic macular edema: what is focal and what is diffuse? Am J Ophthalmol (2008) 1.47
Analysis of macular edema after cataract surgery in patients with diabetes using optical coherence tomography. Ophthalmology (2007) 1.46
Comparison of time- and spectral-domain optical coherence tomography in management of diabetic macular edema. Invest Ophthalmol Vis Sci (2014) 1.45
Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: quality-of-life findings: SST report no. 14. Ophthalmology (2004) 1.42
Responsiveness of the National Eye Institute Visual Function Questionnaire to changes in visual acuity: findings in patients with subfoveal choroidal neovascularization--SST Report No. 1. Arch Ophthalmol (2003) 1.40
New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence. Acta Ophthalmol Scand (2007) 1.40
Surgical removal vs observation for idiopathic or ocular histoplasmosis syndrome-associated subfoveal choroidal neovascularization: Vision Preference Value Scale findings from the randomized SST Group H Trial: SST Report No. 17. Arch Ophthalmol (2008) 1.39
Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci (2008) 1.36
Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic: II. Quality-of-life findings from a randomized clinical trial: SST Group H Trial: SST Report No. 10. Arch Ophthalmol (2004) 1.34
Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol (2004) 1.30
Relative contributions of reduced vision and general health to NEI-VFQ scores in patients with neovascular age-related macular degeneration. Arch Ophthalmol (2004) 1.29
The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after brachytherapy. COMS report no. 19. Ophthalmology (2002) 1.29
Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol (2005) 1.26
Agreement of time-domain and spectral-domain optical coherence tomography with fluorescein leakage from choroidal neovascularization. Ophthalmology (2010) 1.23
Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology (2012) 1.21
Patients' perceptions of the value of current vision: assessment of preference values among patients with subfoveal choroidal neovascularization--The Submacular Surgery Trials Vision Preference Value Scale: SST Report No. 6. Arch Ophthalmol (2004) 1.20
Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol (2004) 1.19
Retinal thickness in people with diabetes and minimal or no diabetic retinopathy: Heidelberg Spectralis optical coherence tomography. Invest Ophthalmol Vis Sci (2012) 1.17
Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema. Ophthalmology (2010) 1.13
Selective expression of a sodium pump isozyme by cough receptors and evidence for its essential role in regulating cough. J Neurosci (2009) 1.12
Detection of new-onset choroidal neovascularization using optical coherence tomography: the AMD DOC Study. Ophthalmology (2012) 1.09
Low luminance visual dysfunction as a predictor of subsequent visual acuity loss from geographic atrophy in age-related macular degeneration. Ophthalmology (2008) 1.06
Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: diabetic retinopathy clinical research network. Retina (2010) 1.04
Use of patient-reported outcomes in medical product development: a report from the 2009 NEI/FDA Clinical Trial Endpoints Symposium. Invest Ophthalmol Vis Sci (2010) 1.03
Validating retinal fundus image analysis algorithms: issues and a proposal. Invest Ophthalmol Vis Sci (2013) 1.03
Dramatic resolution of choroidal neovascular abnormalities after single aflibercept injection following years of ranibizumab use. JAMA Ophthalmol (2013) 1.02
Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. Arch Ophthalmol (2012) 1.01
Effect of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center-involved diabetic macular edema. Retina (2009) 1.01
Optical coherence tomography and cataract surgery. Curr Opin Ophthalmol (2009) 1.01
Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin in the ocular histoplasmosis syndrome: one-year results of an uncontrolled, prospective case series. Ophthalmology (2002) 1.00
Comparing retinal thickness measurements from Cirrus spectral domain- and Stratus time domain-optical coherence tomography. Retina (2010) 1.00
A method of reporting macular edema after cataract surgery using optical coherence tomography. Retina (2008) 0.99
Inferior limited macular translocation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: 1-year visual outcome and recurrence report. Am J Ophthalmol (2002) 0.99
Preferential Hyperacuity Perimeter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology (2005) 0.98
Second primary cancers after enrollment in the COMS trials for treatment of choroidal melanoma: COMS Report No. 25. Arch Ophthalmol (2005) 0.97
Results of a multicenter clinical trial to evaluate the preferential hyperacuity perimeter for detection of age-related macular degeneration. Retina (2005) 0.96
Patients' preferences in choosing therapy for retinal vein occlusions. Retina (2007) 0.95
Clinicopathologic studies of eyes that were obtained postmortem from four patients who were enrolled in the submacular surgery trials: SST Report No. 16. Am J Ophthalmol (2006) 0.95
Iatrogenic choroidal neovascularization occurring in patients undergoing macular surgery. Retina (2002) 0.94
Automated classification of severity of age-related macular degeneration from fundus photographs. Invest Ophthalmol Vis Sci (2013) 0.94
Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7. Arch Ophthalmol (2005) 0.94
Quality of life after iodine 125 brachytherapy vs enucleation for choroidal melanoma: 5-year results from the Collaborative Ocular Melanoma Study: COMS QOLS Report No. 3. Arch Ophthalmol (2006) 0.93
Retinal anastomosis to choroidal neovascularization: a bum rap for a difficult disease. Arch Ophthalmol (2005) 0.93
Designing clinical trials for age-related geographic atrophy of the macula: enrollment data from the geographic atrophy natural history study. Retina (2007) 0.93
Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study. Ophthalmology (2004) 0.93
Use of best and final visual acuity outcomes in ophthalmological research. Arch Ophthalmol (2003) 0.92
Rasch analysis in the development of a simplified version of the National Eye Institute Visual-Function Questionnaire-25 for utility estimation. Qual Life Res (2011) 0.92
Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol (2013) 0.91
Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration. Arch Ophthalmol (2012) 0.91
Anthropometry in the prediction of sleep disordered breathing in HIV-positive and HIV-negative men. Antivir Ther (2010) 0.91
Diabetic macular edema: current and emerging therapies. Middle East Afr J Ophthalmol (2012) 0.90
Macular edema after cataract surgery in eyes without preoperative central-involved diabetic macular edema. JAMA Ophthalmol (2013) 0.90